Award Data

DESCRIPTION (Provided by Applicant): Work performed during the Phase I of this project has demonstrated that formamide induces selective denaturation of DNA in apoptotic cells. This novel effect of formamide on the stability of apoptotic DNA combined with the detection of denatured DNA with monoclonal antibody (MAb)against single-stranded DNA, has made it possi ...

DESCRIPTION: (Adapted from applicant's abstract): A potentially effective way of limiting or preventing drug-induced cochleo- and vestibulo-ototoxicity is monitoring during treatment. However, practical, cost-effective, monitoring programs are difficult to establish due to impractical instrumentation. Current practices also tend to neglect the balance system. Research ...

Approximately one million cases of stone disease are diagnosed in the United States every year and hyperoxaluria is considered to be a major risk factor. Our goal is to reduce the burden of oxalate excretion by the kidneys before the onset of renal failure caused by the oxalate-induced insults of hyperoxaluria, oxalate crystal deposition in tissue, and the formation of calcium oxalate stones. The ...

DESCRIPTION (provided by applicant): Sjogren's syndrome is a human autoimmune disease of the salivary and lacrimal glands that results in a debilitating xerostomia (dry mouth) and xerophthalmia (dry eyes). This syndrome may present as either a primary autoimmune disease or as a secondary autoimmune disease most often concomitant with other connective tissue diseases or diabetes. Although classi ...

DESCRIPTION (provided by applicant): Cytochlor Technology is about to enter a Phase I trial as a radiosensitizer of tumors of the oral cavity and oropharynx with NCI supervision. Our objective is to demonstrate Cytochlor's safety, selectivity and possible efficacy (although efficacy is not the goal of a Phase I trial). Our goal is to move Cytochlor Technology to a mutliinstitutional Phase II clini ...

DESCRIPTION (provided by applicant): At the end of Phase II, we will launch a new commercial product: HYPERPROTEIN. HYPERPROTEIN will be built on an existing software platform, HYPERCHEM, now in its commercial Version 7.5. HYPERCHEM is used in both education and industry to apply molecular modeling and computational chemistry to molecules. The feasibility of placing the HYPERPROTEIN product on th ...

Kigre is developing new scalable high gain broad band rare earth doped laser oscillator/amplifier glass materials & diode pump architectures in support of high energy and high power laser applications. What's new, exciting and different about Kigre's laser glass materials and constructs is the ability to efficiently store and extract 1000-10,000x more laser power from ultra-short gain lengths and ...

In Phase I, LPTI proved f the concept of high efficiency narrow-band mirror in photo-thermo-refractive glass (PTRG) for high power Nd:YAG laser. In Phase II, a number of photo-thermo-refractive diffractive optical elements (PTR HOEs) including both reflecting and transmitting volume gratings, will be fabricated for different types of high power lasers, and high power beam control will be demonstra ...

DESCRIPTION (provided by applicant): Diabetic retinopathy (DR), the leading cause of adult blindness in the United States, is characterized by aberrant neovascularization ultimately leading to blindness. Similarly, choroidal neovascularization is seen in age-related macular degeneration (ARMD), which is the leading cause of blindness in the elderly. Currently, there is no drug treatment for either ...

DESCRIPTION (provided by applicant): This Phase II STTR application is a continuation of a previous Phase I award between the Wright group at Dartmouth College and Promiliad Biopharma. The goal of this application is to continue our efforts to develop novel chemical libraries with the diversity and complexity common to natural products as a marketable product to the pharmaceutical industry. Key to ...